Americans who rely on insulin could see lower out-of-pocket costs after the Federal Trade Commission reached a settlement with Caremark Rx LLC and Zinc Health Services, resolving the agency’s antitrust case against the second of three major prescription-drug middlemen accused of inflating insulin prices through rebate practices. The agreement, recorded on July 14, 2026, follows a similar deal the FTC struck with Express Scripts earlier this year and projects up to $8.5 billion in savings over ten years, according to the Commission, with an additional $4.5 billion in potential savings tied to further terms. The settlement marks the clearest signal yet that the federal government’s campaign to restructure how pharmacy benefit managers handle drug rebates is producing enforceable results rather than just investigative reports.
Why the Caremark Settlement Changes the Drug-Pricing Equation
Pharmacy benefit managers, or PBMs, sit between drugmakers, insurers, and pharmacies, negotiating rebates that are supposed to lower costs. The FTC’s case against the three largest PBMs alleged the opposite: that these middlemen created incentives for manufacturers to raise list prices so that rebates, and the fees tied to them, would grow larger. Patients paying a percentage of the list price at the pharmacy counter absorbed the difference. Insulin became the agency’s test case because list prices for the drug climbed sharply over the past two decades even as net prices paid to manufacturers stayed relatively flat.
The Caremark settlement directly addresses this dynamic by requiring changes to how the CVS Health unit structures its rebate negotiations. According to the FTC, the agreement with Caremark and its affiliate Zinc Health Services imposes limits on rebate-linked compensation, mandates new disclosures to health plans, and restricts contract terms that would steer business toward higher-priced insulin products. While the specific contractual language is detailed and technical, the core idea is straightforward: PBMs should not earn more money simply because a drug’s sticker price is higher.
The FTC had already secured a settlement with Express Scripts in February 2026, establishing a template that included delinking PBM fees from rebate percentages, adding transparency requirements, and offering cost-plus pricing options. Caremark’s agreement follows a similar structure, and together the two deals cover a majority of the commercially insured population that uses PBM services. Because both settlements are structured as consent orders, they are enforceable for 20 years and backed by potential civil penalties if the companies violate their terms.
The practical question is whether these two settlements will push the remaining major PBM, OptumRx, and smaller competitors to adopt similar practices voluntarily. State insurance regulators already track how PBMs report their fee structures in annual filings. If non-settling plans begin shifting away from rebate-linked compensation in those filings over the next 18 months, it would suggest the FTC’s enforcement approach is reshaping the market without requiring new federal legislation. That trend would be visible in state-level data well before any additional federal rulemaking could take effect, offering an early test of whether the agency’s theory of change is working.
FTC’s Two-Year Path from Investigation to Consent Order
The agency’s campaign against PBM pricing practices followed a deliberate sequence. In July 2024, the FTC released an interim staff report based on 6(b) special orders, which compelled the largest PBMs to turn over internal data about their business practices and market structure. That report laid the factual groundwork for what came next by documenting how rebate arrangements and affiliated group purchasing organizations concentrated power in a handful of intermediaries.
Two months later, in September 2024, the Commission filed an administrative action against the three largest PBMs and their affiliated group purchasing organizations, alleging that their rebate practices artificially inflated insulin prices. The complaint described a “chase-the-rebate” cycle in which PBMs favored higher-list-price insulin products because those generated larger rebates and, in turn, larger PBM fees. In the FTC’s telling, this structure not only harmed patients who pay coinsurance based on list prices but also distorted competition among drug manufacturers.
Express Scripts settled first, in February 2026. The Caremark settlement, according to the FTC, resolves the case against the second drug middleman in the same administrative matter and narrows the live dispute to a single large PBM that has yet to reach an agreement. The Commission’s case docket packages the full settlement record, including the Agreement Containing Consent Order, the Proposed Decision and Order, and the agency’s Analysis to Aid Public Comment, in a single timeline entry dated July 14, 2026. Together, these documents explain how the agency translated its earlier factual findings into specific behavioral remedies.
The projected savings figures deserve scrutiny. The FTC states the Caremark settlement could deliver up to $8.5 billion in savings over 10 years and up to $4.5 billion in additional savings. The relationship between these two figures is not fully explained in the available public materials. The $8.5 billion figure appears to represent a baseline projection tied to the core changes in rebate and fee structures, while the $4.5 billion may be contingent on additional compliance terms or broader market adoption. Until the full consent order text is analyzed in detail, the precise conditions that distinguish the two estimates remain unclear, and policymakers should be cautious about treating them as guaranteed outcomes.
What the Caremark Deal Means for Insulin Users
For people who depend on insulin, the most immediate impact of the Caremark settlement is likely to show up in plan design rather than at the manufacturing plant. The agreement does not regulate what drugmakers can charge; instead, it changes how PBMs and health plans select, cover, and price insulin products for their members. If plans begin favoring lower-list-price options or passing through a larger share of rebates to patients, out-of-pocket costs at the pharmacy counter could fall even if manufacturers’ net revenues stay relatively stable.
Coinsurance and deductibles are key here. Many commercial plans require patients to pay a percentage of a drug’s list price until they meet their deductible. Under the rebate-driven model the FTC challenged, that structure meant patients were effectively paying inflated prices that did not reflect the rebates negotiated behind the scenes. By delinking PBM compensation from rebate size and limiting contractual incentives to prioritize high-list-price drugs, the Caremark settlement aims to break that pattern. Over time, that could make it easier for employers and insurers to design benefits that align patient cost-sharing with the true net cost of insulin.
The settlement may also influence competition among insulin manufacturers. If PBMs and their group purchasing organizations are less able to extract revenue from high-list-price, high-rebate products, drugmakers could face stronger pressure to compete on list prices and net costs instead of rebate depth. That shift would not guarantee lower prices, but it would remove one structural barrier that, according to the FTC’s allegations, kept list prices elevated even as net prices stagnated or fell.
What to Watch as the Final PBM Case Proceeds
With two major PBMs now under consent orders, the FTC’s remaining case against the last large middleman will determine whether the agency secures industry-wide coverage through enforcement rather than rulemaking. If the final PBM settles on terms similar to those accepted by Express Scripts and Caremark, nearly the entire commercial market would operate under comparable constraints on rebate-linked compensation and formulary design.
If, instead, the remaining PBM chooses to litigate, the case could test the FTC’s legal theories about how rebate structures can violate antitrust and consumer-protection laws. A litigated outcome would take longer and introduce uncertainty for patients and payers, but it could also generate a judicial opinion that clarifies the boundaries of lawful PBM conduct. In the meantime, the consent orders already in place will function as real-world experiments in whether changing intermediary incentives can meaningfully lower what patients pay for essential drugs like insulin.
For now, the Caremark settlement signals that the federal government is prepared to move beyond reports and hearings to reshape the financial plumbing of the prescription-drug market. The coming years will reveal whether that shift delivers on its promise for the people whose health depends on insulin every day.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
